3.1. Overall Survival and Progression-Free Survival 
DISEASE PROGRESSION
At 5 years, 29 patients (76%) had survived (16 and 13 in the glutamine and placebo groups, respectively). The two groups exhibited similar results in terms of overall survival (glutamine group: 55.2 ± 12.7 months vs. placebo group: 48.3 ± 21.3 months, Of all patients, 26 (68.4%) survived without disease progression (14 and 12 in the glutamine and placebo groups, respectively). The two groups did not demonstrate a significant difference in progression-free survival (glutamine group: 46.7 ± 19.5 months vs. placebo group: 43.6 ± 25.2 months, 